However, despite these difficulties, ponatinib induced tumor regression in all treated mice (Supplementary Fig. 8f), indicating that the mechanism of D/T + nilotinib resistance may involve ABL1 or ABL2 mutation. This evidence concerns the gene ABL1 and neoplasm.